Oral Low-Dose Glucocorticoids Should Be Included in Any Recommendation for the Use of Non-Biologic and Biologic Disease-Modifying Antirheumatic Drugs in the Treatment of Rheumatoid Arthritis

Publisher： Karger

E-ISSN： 1423-0216|22|1-2|104-111

ISSN： 1021-7401

Source： Neuroimmunomodulation, Vol.22, Iss.1-2, 2014-09, pp. : 104-111

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Trials Documenting the Efficacy of Low-Dose Glucocorticoids in Rheumatoid Arthritis

By  

Neuroimmunomodulation, Vol. 22, Iss. 1-2, 2014-09 ,pp. : 46-50

Karger

Access to resources Recommend Favorite

Circadian Use of Glucocorticoids in Rheumatoid Arthritis

By  

Neuroimmunomodulation, Vol. 22, Iss. 1-2, 2014-09 ,pp. : 33-39

Karger

Access to resources Recommend Favorite

The Safety of Low-Dose Glucocorticoids in Rheumatic Diseases: Results from Observational Studies

By  

Neuroimmunomodulation, Vol. 22, Iss. 1-2, 2014-09 ,pp. : 72-82

Karger

Access to resources Recommend Favorite

Safety of Glucocorticoids in Rheumatoid Arthritis: Evidence from Recent Clinical Trials

By  

Neuroimmunomodulation, Vol. 22, Iss. 1-2, 2014-09 ,pp. : 57-65

Karger

Access to resources Recommend Favorite

The Past versus the Present, 1980-2004: Reduction of Mean Initial Low-Dose, Long-Term Glucocorticoid Therapy in Rheumatoid Arthritis from 10.3 to 3.6 mg/Day, Concomitant with Early Methotrexate, with Long-Term Effectiveness and Safety of Less than 5 mg/Day

By  

Neuroimmunomodulation, Vol. 22, Iss. 1-2, 2014-09 ,pp. : 89-103

Karger

Access to resources Recommend Favorite